Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

28.66 -0.81 (-2.75%)
Streaming Delayed Price Updated: 10:40 AM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Chief Financial Officer Transition
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis and Padagis Agree to Stay Patent Lawsuit
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.